Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Cardiology

Managing Heart Failure When You Have LVNC

At a Glance

When LVNC causes symptomatic heart failure with reduced ejection fraction, treatment usually follows standard heart-failure care: four medication classes support heart function, while diuretics relieve fluid buildup. Doses are tailored to blood pressure, kidney function, potassium, and tolerance.

If your doctor tells you that your Left Ventricular Noncompaction (LVNC) has led to reduced pumping function (a low ejection fraction), you may have a condition known as Heart Failure with Reduced Ejection Fraction (HFrEF) [1]. It is important to note that a low ejection fraction alone is just a measurement; HFrEF refers to the clinical syndrome where this weakness causes symptoms like shortness of breath or swelling.

One of the most important things to understand is that there is no “LVNC-specific” pill [2]. The spongy look is a structural trait, but the medications are there to support the heart’s action [3]. Doctors use a powerful, evidence-based combination of medications known as Guideline-Directed Medical Therapy (GDMT) [4]. This treatment is driven by your heart’s function and your individual health profile, not by how “spongy” the heart looks on a scan [5][6].

The Four Pillars of Treatment

Modern heart failure care is built on four “pillars” of medication. These drugs work together to take the stress off your heart muscle, prevent it from getting larger, and help it pump more effectively [7][8].

  1. ARNI, ACE Inhibitor, or ARB: These medications (like sacubitril/valsartan, lisinopril, or losartan) help relax your blood vessels and lower blood pressure, making it much easier for your heart to push blood out to the rest of your body [9][10]. Safety note: You must never combine an ACE inhibitor with an ARNI (sacubitril/valsartan), as this can cause a life-threatening reaction. These drugs can also lower your blood pressure, so your doctor will monitor you carefully [11].
  2. Beta-Blockers: Drugs such as carvedilol, metoprolol succinate, or bisoprolol act like a “brake” for your heart [12]. They slow your heart rate and protect the muscle from stress hormones.
  3. Mineralocorticoid Receptor Antagonists (MRAs): Medications like spironolactone or eplerenone are “potassium-sparing” diuretics that block a hormone called aldosterone, which causes the heart to develop stiff, scarred tissue [13][14]. Safety note: These drugs can raise potassium levels [15]. Your kidney function and potassium must be closely monitored by your doctor, as some heart medications change how your kidneys filter blood [16][17].
  4. SGLT2 Inhibitors: Drugs like dapagliflozin or empagliflozin help the kidneys remove excess sugar and sodium, reducing the overall workload on the heart [18][19]. Safety note: You may need to pause these medications if you are very sick (like with severe vomiting or diarrhea) or having surgery, as part of “sick-day rules.” Always ask your doctor.

Managing Fluid: The Role of Diuretics

If you have “congestion”—meaning your body is holding onto too much fluid—you may experience swelling in your legs or shortness of breath [20]. To fix this, doctors prescribe diuretics (often called “water pills”), such as furosemide or bumetanide [21].

Unlike the “four pillars” which help your heart function long-term, diuretics are primarily used to manage symptoms [22]. Do not start, stop, or change your diuretic dose on your own. You should follow a specific action plan provided by your clinician based on your daily weight [23].

Finding Your Target Dose

The goal of heart failure treatment is to reach the target dose—the amount of medicine shown in clinical trials to provide the most benefit [4]. However, this is highly individualized. The exact mix and dose of medications depends on your blood pressure, kidney function, potassium levels, and how well you tolerate the drugs. Not all patients can reach the maximum trial doses, and that is okay [8].

Your care team will slowly increase your doses over time (titration). During this period, keep in mind:

  • Pregnancy: If you are pregnant or planning to become pregnant, contact your care team immediately. Many of these medications (like ACE inhibitors, ARBs, ARNIs, and MRAs) are not safe during pregnancy and must be changed.
  • Call Your Team If: You experience severe dizziness, fainting, chest pain, breathlessness at rest, or rapid fluid-weight gain (e.g., 2-3 pounds overnight or 5 pounds in a week).

Common questions in this guide

What medicines are used when LVNC causes heart failure?
When LVNC causes symptomatic heart failure with reduced ejection fraction, clinicians generally use standard evidence-based heart failure treatment rather than an LVNC-specific pill. Treatment often includes four medication groups chosen according to your blood pressure, kidney function, potassium level, symptoms, and tolerance.
What are the four main medication groups for LVNC-related heart failure?
The four groups are an ARNI, ACE inhibitor, or ARB; a beta-blocker; a mineralocorticoid receptor antagonist; and an SGLT2 inhibitor. An ACE inhibitor must not be taken together with an ARNI such as sacubitril/valsartan because the combination can cause a serious reaction.
Why might I need a diuretic or water pill?
Diuretics such as furosemide or bumetanide help remove extra fluid when heart failure causes swelling or shortness of breath. They mainly relieve congestion symptoms and should not be started, stopped, or adjusted without the action plan from your clinician.
How do doctors decide the right dose of my heart failure medicines?
Your care team usually increases doses gradually toward a target dose used in clinical studies, if you can safely tolerate it. Blood pressure, kidney function, potassium levels, heart rate, and side effects determine the dose, and not everyone can reach the maximum trial dose.
What symptoms should prompt me to call my heart failure team?
Call your team about severe dizziness, fainting, chest pain, breathlessness at rest, or rapid weight gain such as 2 to 3 pounds overnight or 5 pounds in a week. Swelling, worsening shortness of breath, or needing more pillows may also signal fluid buildup and should be discussed.
Are LVNC heart failure medicines safe during pregnancy?
Many commonly used medicines, including ACE inhibitors, ARBs, ARNIs, and mineralocorticoid receptor antagonists, may be unsafe during pregnancy. Contact your care team immediately if you are pregnant or planning to become pregnant so your treatment can be reviewed safely.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Left ventricular noncompaction.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current ejection fraction, and does it qualify for the 'four pillars' of heart failure therapy?
  2. 2.Am I currently on the target doses for my beta-blocker and ARNI/ACE inhibitor, or is there room to safely increase them?
  3. 3.How do my kidney function and potassium levels affect which heart failure medications I can take?
  4. 4.Should I be monitoring my weight and blood pressure daily at home to help adjust my diuretic dose?
  5. 5.If my heart function doesn't improve on these medications, what are the next steps in my treatment plan?

References

References (23)
  1. 1

    What happened to the left ventricular non-compaction cardiomyopathy? to be or not to be: This is the question.

    Di Lisi D, Macaione F, Damiani F, et al.

    Current problems in cardiology 2024; (49(11)):102787 doi:10.1016/j.cpcardiol.2024.102787.

    PMID: 39137881
  2. 2

    Left Ventricular Non-compaction Cardiomyopathy: A Case Report and Literature Review.

    Elkattawy S, Romero J, Shah K, et al.

    Journal of community hospital internal medicine perspectives 2023; (13(3)):69-71 doi:10.55729/2000-9666.1168.

    PMID: 37877059
  3. 3

    Bridging the gap between hypertrabeculation phenotype, noncompaction phenotype and left ventricular noncompaction cardiomyopathy.

    Vergani V, Lazzeroni D, Peretto G

    Journal of cardiovascular medicine (Hagerstown, Md.) 2020; (21(3)):192-199 doi:10.2459/JCM.0000000000000924.

    PMID: 31895132
  4. 4

    Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction.

    Ospina González OE, Llanos Mejía DC, Kaplinsky E, et al.

    Drugs in context 2023; (12()) doi:10.7573/dic.2022-6-4.

    PMID: 36660017
  5. 5

    Prognostic Significance of Left Ventricular Noncompaction: Systematic Review and Meta-Analysis of Observational Studies.

    Aung N, Doimo S, Ricci F, et al.

    Circulation. Cardiovascular imaging 2020; (13(1)):e009712 doi:10.1161/CIRCIMAGING.119.009712.

    PMID: 31959004
  6. 6

    Long-Term Survival of Patients With Left Ventricular Noncompaction.

    Vaidya VR, Lyle M, Miranda WR, et al.

    Journal of the American Heart Association 2021; (10(2)):e015563 doi:10.1161/JAHA.119.015563.

    PMID: 33441029
  7. 7

    Guidelines for treating heart failure.

    Kittleson MM

    Trends in cardiovascular medicine 2025; (35(3)):141-150 doi:10.1016/j.tcm.2024.10.002.

    PMID: 39442740
  8. 8

    Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.

    Malgie J, Clephas PRD, Brunner-La Rocca HP, et al.

    Heart failure reviews 2023; (28(5)):1221-1234 doi:10.1007/s10741-023-10325-2.

    PMID: 37311917
  9. 9

    Angiotensin-Neprilysin Inhibition as a Paradigm for All?

    Vaduganathan M, Desai AS

    Current cardiology reports 2016; (18(11)):115 doi:10.1007/s11886-016-0784-z.

    PMID: 27747488
  10. 10

    Improving the Management of Patients with Heart Failure with Reduced Ejection Fraction in Clinical Practice: The Case for Angiotensin Receptor-Neprilysin Inhibitor.

    Iacoviello M, Maria Sarullo F, Bilato C, et al.

    Cardiac failure review 2025; (11()):e16 doi:10.15420/cfr.2024.39.

    PMID: 40741340
  11. 11

    Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: Statement from a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology.

    Mewton N, Girerd N, Boffa JJ, et al.

    Archives of cardiovascular diseases 2020; (113(10)):660-670 doi:10.1016/j.acvd.2020.03.018.

    PMID: 32660835
  12. 12

    Looking for the ideal medication for heart failure with reduced ejection fraction: a narrative review.

    Pascual-Figal D, Bayes-Genis A

    Frontiers in cardiovascular medicine 2024; (11()):1439696 doi:10.3389/fcvm.2024.1439696.

    PMID: 39314771
  13. 13

    European Journal of Heart Failure International Expert Position Paper-Utilization, optimization, and clinical benefits of steroidal mineralocorticoid receptor antagonists in heart failure with a reduced ejection fraction.

    Böhm M, Abdullakutty J, Bauersachs J, et al.

    European journal of heart failure 2026; (28(3)):513-534 doi:10.1093/ejhf/xuag106.

    PMID: 41955577
  14. 14

    Sudden cardiac arrest as the initial presentation for left ventricular noncompaction cardiomyopathy.

    Jakkoju A, Jakkoju R, Kuchana V, et al.

    Proceedings (Baylor University. Medical Center) 2019; (32(4)):564-566 doi:10.1080/08998280.2019.1627781.

    PMID: 31656421
  15. 15

    Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.

    Desai AS, Vardeny O, Claggett B, et al.

    JAMA cardiology 2017; (2(1)):79-85 doi:10.1001/jamacardio.2016.4733.

    PMID: 27842179
  16. 16

    Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction.

    McCallum W, Tighiouart H, Ku E, et al.

    Kidney international 2019; (96(5)):1185-1194 doi:10.1016/j.kint.2019.05.019.

    PMID: 31420191
  17. 17

    Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.

    Beldhuis IE, Lam CSP, Testani JM, et al.

    Circulation 2022; (145(9)):693-712 doi:10.1161/CIRCULATIONAHA.121.052792.

    PMID: 35226558
  18. 18

    Heart Failure With Reduced Ejection Fraction: A Review.

    Murphy SP, Ibrahim NE, Januzzi JL

    JAMA 2020; (324(5)):488-504 doi:10.1001/jama.2020.10262.

    PMID: 32749493
  19. 19

    Managing Heart Failure With Reduced Ejection Fraction in Patients With Chronic Kidney Disease: A Case-Based Approach and Contemporary Review.

    Barry AR

    CJC open 2022; (4(9)):802-809 doi:10.1016/j.cjco.2022.06.007.

    PMID: 36148258
  20. 20

    Change in renal function associated with drug treatment in heart failure: national guidance.

    Clark AL, Kalra PR, Petrie MC, et al.

    Heart (British Cardiac Society) 2019; (105(12)):904-910 doi:10.1136/heartjnl-2018-314158.

    PMID: 31118203
  21. 21

    Heart failure with reduced ejection fraction.

    Cannata A, Crespo-Leiro MG, Bromage DI, et al.

    Lancet (London, England) 2026; (407(10527)):529-542 doi:10.1016/S0140-6736(25)01851-3.

    PMID: 41319669
  22. 22

    Management of Heart Failure With Reduced Ejection Fraction.

    Rashid AM, Khan MS, Fudim M, et al.

    Current problems in cardiology 2023; (48(5)):101596 doi:10.1016/j.cpcardiol.2023.101596.

    PMID: 36681212
  23. 23

    Diuretics in the management of chronic heart failure: when and how.

    Magdy JS, McVeigh J, Indraratna P

    Australian prescriber 2022; (45(6)):200-204 doi:10.18773/austprescr.2022.069.

    PMID: 36479331

This page explains heart failure medicines and monitoring when LVNC affects pumping function for informational purposes only and does not constitute medical advice. Your cardiology or heart-failure care team should guide treatment decisions for your situation.